• About Us
  • Our Approach
    • Discovery Platform
  • Pipeline
    • HMBD-001
    • HMBD-002
    • HMBD-501
  • News
  • Careers

What are you looking for?

Hummingbird Bioscience
Hummingbird Bioscience
Hummingbird Bioscience
  • About Us
  • Our Approach
    • Discovery Platform
  • Pipeline
    • HMBD-001
    • HMBD-002
    • HMBD-501
  • News
  • Careers
    Category Archives

    Publications & Posters

  • All
  • Publications & Posters – 2022
  • Publications & Posters – 2017
  • Publications & Posters – 2018
  • Publications & Posters – 2020
  • Publications & Posters – 2021
    • Publications & Posters
    • Publications & Posters - 2022

    SITC 2022: Anti-VISTA antibody HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T cell response

    Continue Reading
    • Publications & Posters
    • Publications & Posters - 2022

    SITC 2022: Trial in Progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

    Continue Reading
    • Publications & Posters
    • Publications & Posters - 2022

    Journal for ImmunoTherapy of Cancer: Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.

    Continue Reading
    • Publications & Posters
    • Publications & Posters – 2021

    SITC 2021: A Phase 1 First-in-Human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

    Continue Reading
    • Publications & Posters
    • Publications & Posters – 2021

    AACR-NCI-EORTC Virtual International Conference 2021: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1 fusion driven cancers

    Continue Reading
    • Publications & Posters
    • Publications & Posters – 2021

    American Association for Cancer Research 2021: Dual-specific antibodies that bind to BCMA and TACI (HMBD-009) enable better targeting of multiple myeloma in pre-clinical models

    Continue Reading
    • Publications & Posters
    • Publications & Posters – 2021

    AACR 2021: Dual-specific biotherapeutics targeting BCMA and TACI have the potential to overcome resistance mechanisms in multiple Myeloma

    Continue Reading
    • Publications & Posters
    • Publications & Posters – 2020

    The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

    Continue Reading
    • Publications & Posters
    • Publications & Posters – 2020

    Molecular Cancer Therapeutics, AACR Journals: 10D1F, an anti-HER3 antibody that uniquely blocks the receptor heterodimerization interface, potently inhibits tumor growth across a broad panel of tumor models

    Continue Reading
    • Publications & Posters
    • Publications & Posters – 2018

    Journal for ImmunoTherapy of Cancer: P477 HMBD-002-V4: A novel anti-VISTA antibody that uniquely binds murine and human VISTA and potently inhibits tumor growth by remodeling the immunosuppressive tumor microenvironment

    Continue Reading
  • 1
  • 2
  • →

Hummingbird Bioscience

TMC Innovation
2450 Holcombe Blvd, Suite X
Houston, TX 77021

The Galen
61 Science Park Road, #06-15/24,
Singapore 117525

For general enquiries, please contact contact@hummingbirdbio.com

For career enquiries, please contact careers@hummingbirdbio.com

For business development opportunities, please contact bd@hummingbirdbio.com


Hummingbird Bioscience Twitter Hummingbird Bioscience Twitter Hummingbird Bioscience LinkedinHummingbird Bioscience Linkedin Hummingbird Bioscience YouTube Hummingbird Bioscience YouTube
Subscribe to our updates
Registered Company No: 201505192N
PRIVACY POLICY | © 2022 Hummingbird Bioscience

Subscribe to our updates

    *indicates required

    GDPR Marketing Permissions

    *Please select all the ways you would like to hear from Hummingbird Bioscience:

    You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website. For questions about this mailing list, please email communications@hummingbirdbio.com

    We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.